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Abstract
Clients with end-stage renal disease (ESRD) often experience
an associated anemia which has been attributed to an
endocrine deficiency of erythropoietin.

The purpose of this

descriptive, retrospective study was to describe the
characteristics of the effectiveness of erythropoietin (EPO)
therapy on the anemia associated with ESRD.

The research

question generated was how effective is EPO therapy in the
treatment of the anemia in clients with ESRD in Mississippi?
Orem's Self-Care Model was the theoretical framework used
for this study.

The sample (N = 100) consisted of 55 males

clients and 45 female clients from an ambulatory dialysis
unit in Northeast Mississippi.
dialysis and EPO therapy.

The clients were receiving

The researcher designed an

instrument for data collection.

Demographic findings, blood

pressure, and blood transfusions were analyzed using
descriptive statistics, including means, percentages, and
frequencies.

A paired t test was utilized to analyze the

statistical significance between pretherapy and posttherapy
hematocrit data.

Findings indicated a significant increase

in hematocrits at one month posttherapy, t = -4.12, p < .05;
3 months, t = -7.45 p < .05; and current levels, t = -8.58,
p < .05.

The mean baseline hematocrit was 24.56, and the

V

mean current hematocrit was 29.79.
increase, t = 21.25, p > .05.

Blood pressures did not

The mean pretherapy systolic

blood pressure was 169.57, and the mean posttherapy systolic
pressure was 153.63.

The mean diastolic blood pressure was

101.33, and the posttherapy mean diastolic pressure was
86.86.

This study did not show a significant decrease in

blood transfusion requirements.

Eighty-eight percent of the

clients did not receive transfusions pretherapy, and 79% did
not receive transfusions posttherapy.

The researcher

concluded that EPO is effective in increasing hematocrit
levels in the client with ESRD.

Similar studies are needed

to further document the effectiveness of EPO on the anemia
of ESRD in clients in Mississippi.

Implications for nursing

include the importance of education, documentation, and
continuity of care in health promotion and rehabilitation of
the client with ESRD.
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Chapter I
The Research Problem
Introduction to the Problem
End-stage renal disease (ESRD) is a serious health
problem in the United States.

As of 1991, there were

142,488 people in the United States on some form of dialysis
for the treatment of ESRD (Health Care Financing
Administration,

1992).

Mississippi statistics show a total

of 2,236 ESRD clients in the state (ESRD Network,

1991).

The number of people with ESRD is increasing yearly due to
medical technology, such as dialysis which is extending the
life of these clients.

The focus of health care providers

has been on increasing life expectancy.

In doing so, health

care providers have overlooked the quality of life.
The impact of ESRD on the client's life is extensive.
The disease is characterized by symptoms related to the
retention of uremic toxins (uremia) which results from loss
of renal function (Luckmann & Sorenson,

1987).

Early

manifestations of uremia are fatigue and decreased mental
acuity.

As renal function declines, other symptoms appear

which may include the following:

nausea, vomiting,

anorexia, cramps and muscular twitching, cold sensitivity.

2
and decreased exercise tolerance.

In addition, some clients

may experience angina and cardiac failure.
The symptoms of uremia can have a profound effect on
clients.

Lowered energy levels may result in decreased

participation in vocational roles, household chores, and
community and social activities.

Also, cognitive function

may decline, self-esteem may lessen, mood changes may occur,
and the general sense of well-being may diminish (Nissenson,
1989).
The symptomatology presented by ESRD was once primarily
attributed to uremia.

However, it is now apparent that many

of these symptoms are those related to the associated
anemia.

The symptoms of the anemia include fatigue, angina,

exertional dyspnea, palpitations, cold sensitivity,
anorexia, decreased or loss of sexual functioning, pallor,
menstrual irregularities, and tachycardia.

Cardiac failure,

with reversible cardiac enlargement, cardiac bruits, and
pulmonary and peripheral edema may develop if the anemia is
severe (Stevens, Kurtz, Eckardt, & Winearls,

1992).

Anemia is an almost universal complication of ESRD.
Approximately three fourths of the patients on dialysis in
the United States have symptoms of anemia.

Many more

predialysis clients also suffer from this complication.

The

severity of the anemia varies, depending on the underlying
renal disease.

Higher hematocrits are observed in clients

with polycystic kidney disease and lower hematocrits in
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those with interstitial disease.

The hematocrit starts

decreasing when the glomerular filtration rate (GFR) falls
below 50 ml per minute.

Dialysis therapy is usually

initiated when GFR is below 10 ml per minute.

Dialysis can

result in improvement of many of the symptoms of uremia;
however, it does not completely reverse the uremic milieu.
Therefore, the client is left in a chronic state of uremia
and vulnerable to the many complications of uremia,
including anemia.

The average hematocrit for the ESRD

client (prior to erythropoietin therapy) is 21% to 23%.
Therefore, the anemia of chronic renal failure contributes
significant morbidity to the clients on dialysis because of
the associated symptoms (Rosenberg,

1992).

The anemia associated with ESRD has been recognized
since 1836.
anemia.

However, very little was understood about this

The etiology of the anemia has been attributed to

many factors, but only in recent years has its pathogenesis
emerged (Eschbach, Haley, & Adamson,

1990).

The etiology of the anemia associated with ESRD is
multifactorial, but the primary cause is thought to be an
endocrine deficiency of erythropoietin.

Although shortened

survival of red blood cells, blood loss through dialysis,
and uremic toxins that inhibit marrow erythropoiesis may
contribute to the anemia, studies indicate that inadequate
erythropoietin production is the single most important cause
(Duff, 1989).
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The process of erythropoiesis is complex and not fully
understood.

The normal kidneys produce 90% of the

erythropoietin, and the liver produces 10%.

When anemia

develops, the resulting hypoxia stimulates the release of
erythropoietin hormone which increases plasma
erythropoietin.

Erythropoiesis occurs until the anemia is

corrected, and the plasma erythropoietin returns to normal
ranges.

In this process there is a feedback relationship

between the hematocrit and the plasma erythropoietin.

The

damaged kidneys in progressive renal failure cannot maintain
a balance of homeostasis.

Anemia develops and worsens with

increasing tissue destruction (Eschbach et al., 1990).
In the past, anemia associated with ESRD has been
treated with limited success.

According to Stevens et al.,

(1992), treatments have included dialysis, androgen therapy,
and red blood cell transfusions.

With dialysis,

improvement

in the anemia is often seen within a few months.
Improvement is dependent on the intensity of the dialysis.
Androgen therapy has shown improvement when given parentally
and in association with adequate dialysis.

However, not all

clients respond to androgen therapy, and there have been
incidences of side effects in up to 25% of the clients.
Blood transfusions given as a treatment for the anemia
results in suppression of erythron activity and increases
the requirement for subsequent transfusions.

Frequent

transfusions increase the client's risk of iron overload.
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blood-borne viral infections, and risk of exposure of
antibody production to HLA antigens which reduces the chance
of receiving a successful transplant (Stevens et al.,

1992).

Despite advances in understanding the physiology of the
anemia associated with ESRD, naturally occurring
erythropoietin cannot be obtained in sufficient quantities
to treat the anemia.

However, erythropoietin has been

cloned through genetic coding.

Recombinant human

erythropoietin (r-HuEPO or EPO) has been developed, and it
has a similar structure to the native human erythropoietin.
This erythropoietin clone has been studied in world-wide
clinical trials and is now being used in the treatment of
the anemia associated with ESRD (Duff, 1989).

Since

approval for use in 1989 by the Food and Drug
Administration, EPO has become a mainstay of therapy in the
clients with ESRD (Rosenberg,

1992).

Significance to Nursing
Anemia is a major predictable complication of ESRD.

It

is often severe and hinders rehabilitation even though the
client receives adequate dialysis.

Anemia also affects the

client's physiological and psychological functioning and
social and vocational participation.

Therefore, this study

will enhance the nurse clinician's understanding of the
impact of ESRD associated anemia on the client's life, as
well as the pathogenesis of the anemia.

6
In addition, this study will increase the availability
of current nursing research on ESRD, as well as increasing
nursing awareness of the effectiveness of EPO on the anemia
as indicated by improvement in symptomatology.

The

decreased requirement for blood transfusions will also
benefit nursing by decreasing the possibility of contracting
infection from blood-borne pathogens through handling of
blood products.

Also, by understanding the anemic state and

the improvement in the anemic state by EPO, the nursing
agent will be better prepared for appropriate history and
physical assessment, teaching, and establishing intervention
modalities directed toward rehabilitation of the client to a
more productive lifestyle.
Theoretical Framework
Orem's Self-Care Model was the theoretical framework
selected for this study.
related theories:

Within this model there are three

the Theory of Self-Care, the Theory of

Self-Care Deficit, and the Theory of Nursing Systems
(Marriner-Tomey,

1989).

These theories contain propositions

vital to health promotion, such as health maintenance,
prevention, care, rehabilitation, and functional living with
a disease or disability (Riehl-Sisca,

1989).

The Theory of

Self-Care describes self-care as the ability to provide for
oneself.

The Theory of Self-Care Deficit identifies

limitations the client has in meeting self-care and how
nursing could intervene.

The Theory of Nursing Systems
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gives knowledge of a client's self-care demands and provides
assistance in meeting these demands (Orem, 1985).

Within

the nursing systems, the client's self-care demands are met
through one of the three systems (wholly compensatory,
partly compensatory, and supportive-educative) depending on
the ability of the client to meet the demands and the degree
of nursing intervention needed (Marriner-Tomey,

1989).

Orem defined four metaparadigm concepts including
person, nursing, environment, and health.

The person is a

whole of inseparable physical, psychological,
and social factors.

interpersonal,

Nursing is an active process to

overcome or prevent the development of self-care deficits or
provide therapeutic care for an individual who is unable to
perform self-care.

The environment consists of elements

external to the individual.

Health is the stability of

internal and external conditions which permits the
individual to perform self-care (Leddy & Pepper,

1989).

Within the framework of this study, the person was
identified as the client with ESRD receiving EPO therapy for
the treatment of associated anemia.

Nursing represents the

process of identifying the effectiveness of EPO therapy.
The environment was the ambulatory dialysis unit with which
the client was associated.

Health was reflected by the

therapeutic response to EPO therapy.

Orem's Self-care Model

provided structure and organization to this study through
clear, identifiable definitions.

Also, the propositions
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vital to health promotion were applicable to the client with
ESRD since care is directed toward maintenance, prevention,
and rehabilitation.
Assumptions
The assumptions on which this study was based were
1.

Persons require continuous deliberate inputs to

themselves and their environment to remain alive and
functioning.
2.

Mature persons experience privations in the form

of limitations for self-care actions and care of others
involving making life-sustaining and function-regulating
inputs.
3.

Human agency is experienced in identifying,

developing, and transmitting to others the ways and means to
identify requisites for and make inputs to self and others
(Marriner-Tomey,

1989).

Purpose of the Study
The purpose of this study was to evaluate the
effectiveness of recombinant human erythropoietin therapy in
the treatment of the anemia in clients with ESRD in
Mississippi.
Statement of the Problem
The problem evaluated was the degree of improvement in
the anemia associated with ESRD following initiation of

recombinant human erythropoietin therapy as part of the
therapeutic medical regimen.
Research Question
The research question generated was this :

How

effective is recombinant human erythropoietin therapy in the
treatment of the anemia in clients with ESRD in Mississippi?
Definition of Terms
For the purpose of this study, the following terms were
identified:
Client :

A person who is receiving recombinant human

erythropoietin therapy (r-HuEPO, EPO) for the treatment of
the anemia associated with ESRD, on some form of dialysis,
and living in Mississippi.
End-stage Renal Disease (ESRD):

An irreversible

progressive reduction of functioning renal tissue which can
no longer maintain the body's internal environment and
necessitates treatment with dialysis or kidney transplant
for survival (Luckmann & Sorenson,
Anemia :

1987).

A decrease in oxygen-carrying capability of

the blood with a hematocrit value less than 37% in females
and 42% in males and associated with ESRD.
Effective erythropoietin therapy:

Recombinant human

erythropoietin is a clone of the naturally occurring
erythropoietin hormone which stimulates the process of
erythropoiesis and is used in the treatment of the anemia
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associated with ESRD.

In the therapeutic response, the

hematocrit level will be 33% or greater, and the client will
be independent of blood transfusions except for the
replacement of blood loss.

Chapter II
Review of the Literature
Review of the literature revealed an active interest by
physicians and researchers in the treatment of the anemia
associated with ESRD.

The available literature is from

current clinical trials.

Some of the clinical trials are

ongoing, and the data are not yet available.

However, one

available study by Eschbach, Egrie, Downing, Browne, and
Adamson (1987) evaluated the effects of intravenous EPO
given three times a week to 25 hemodialysis clients.

Prior

to initiating the study, the participants underwent
extensive medical evaluation.

Criteria for client

participation was met and included the following;
hematocrit < 2 5 ,

on hemodialysis for at least 3 months,

medically stable, controlled hypertension or no
hypertension, not pregnant, no evidence of hemolysis or
blood loss, no evidence of toxic effects of aluminum, not
receiving androgen or immunosuppressive therapy, serum
aspartate aminotransferase stable or no more than twice
normal, and no evidence of other systemic illness that may
mask the effectiveness of EPO therapy.
Recombinant human erythropoietin was given
intravenously three times a week after dialysis.
11

Response
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to the therapy was evaluated by the effect on blood
transfusion requirements, hematocrit,

ferrokinetics, and

reticulocyte response.
Dose dependent increases in effective erythropoiesis
were observed.

Dosages ranged between 15 and 500 units per

kilogram of body weight (u/kg).

At the maximum dose,

changes of at least 10 percentage points were observed in
the hematocrit within 3 weeks.

The ferrokinetics increased

three to four times basal values.

Twelve clients out of 18

no longer required blood transfusions, and 11 had hematocrit
increases of 35% or more.

Four of the clients with

hematocrit increases experienced an increase in blood
pressure and one had a grand mal seizure.

However, this

client had had a similar type seizure 3 years prior to the
study but was not receiving anticonvulsant therapy.

The

majority of the clients had increased serum creatinine and
potassium levels.

Functional iron deficiency developed at

doses of 15 u/kg or more.

Twelve of the 18 clients received

intravenous iron dextran and one (allergic to iron dextran)
was administered oral iron therapy.

Iron excess decreased

in all clients who responded to EPO therapy.

No antibodies

developed in response to EPO, no organ dysfunction occurred,
nor were other toxic effects observed.
Another study by Watson, Gimenez, Cotton, Walser, and
Spivak (1990) evaluated the efficacy of subcutaneous EPO
therapy in clients with chronic renal failure and anemia
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{predialysis).

Eleven clients participated in the

double-blind, placebo controlled study.

The EPO group

received subcutaneous 100 u/kg body weight three times per
week, and the other group received a placebo injection.
After 12 weeks the placebo group received EPO 150 u/kg three
times a week until a target hematocrit was achieved.

During

the study, blood pressure was monitored, and blood work was
obtained regularly for hematocrit, hemoglobin, reticulocyte
count, and iron profile determinations.
Statistical analysis was done using the Student's t
test for unpaired

data.

The mean baseline

hematocrit of both groups was similar;

EPO, 29% + 2% and

placebo, 28% + 2%. After 12 weeks, the

hematocrit of the

treated group had increased to 35% + 2 %

< 0.001).

Values were expressed as mean + SE.

The placebo group was 26% + 2%.

(p

After 12 weeks

of EPO therapy, the placebo group had a significant increase
in hematocrit to 32% + 2 %

(p < 0.001 versus baseline).

Baseline blood pressures in the EPO group were 169/83, after
12 weeks 136/76, and 144/78 at 52 weeks.

The placebo

group's baseline mean blood pressures were 135/75,

149/83 at

12 weeks, and 139/81 at 52 weeks.
One placebo-treated client had a seizure related to
hyponatremia after ingestion of water load in preparation
for glomerular filtration rate estimate.

One EPO client

experienced numbness of fingers of the right hand during the
maintenance phase when the hematocrit was stable.

This was
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thought to be related to a transient ischemic attack.

The

significance of the two studies is that they indicate that
EPQ therapy is effective in treatment of anemia of chronic
renal failure in both hemodialysis and predialysis clients.
However, clients receiving continuous ambulatory peritoneal
dialysis

(CAPD) also benefit from EPO therapy.

The recommended route of administration for the
predialysis and CAPD clients is subcutaneous, since self
administration can be easily taught.

Subcutaneous

administration is also feasible in the hemodialysis client.
However, intravenous administration is recommended only for
the hemodialysis patient.
The recommended dose range to maintain a stable
hematocrit (35 + 3) varies between 15 and > 300 u/kg,
intravenously three times a week, with a median of 75 u/kg.
The frequency of dosing is dependent upon the route.
Because of pharmacokinetics, the intravenous dose must be
given two to three times per week.

However, weekly

subcutaneous administrations of EPO are as effective as the
same total dose divided into three 15 u/kg doses/week
(Eschbach et el., 1990).
The recommended target range for the hematocrit level
is 33% to 40% in order to achieve maximum benefits from
oxygen delivery and to reduce side effects.

Therefore, the

dosage is dependent on the client's response to EPO.

The

best starting dose is in the lowest range which produces
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gradual but consistent increases in the hematocrit (Duff,
1989) .
Treatment with EPO stimulates erythropoiesis,

increases

hematocrit levels, and eliminates blood transfusion
requirements in virtually all hemodialysis clients with
uncomplicated anemia (no iron deficiency,
other signs of aluminum toxicity)

inflammation, or

(Nissenson,

1989).

However, there have been other positive effects from EPO
therapy demonstrated in clients.
Positive effects on the hematocrit from treatment with
EPO therapy extends to other subjective and objective
improvements.

The subjective benefits include improvement

in sexual functioning, increased energy levels, and better
sleep patterns.

The objective improvements include an

increase in brain and cognitive function and exercise
tolerance.
A study cited by Nissenson (1989) measured brain
event-related potentials in 13 clients receiving
hemodialysis, before and after 12 weeks of EPO therapy.

The

mean hematocrit level increased from 22.7% at initiation of
the study to 36.6% after treatment.

Nine of 13 clients

demonstrated improvement in P3 latencies with tone and vowel
stimuli, indicating fast and more efficient information
processing by the brain.

This study was extended to 17

clients receiving hemodialysis and EPO for at least one
year.

Mean hematocrit levels increased from 23% prior to
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EPO to 37% in a year.

Improvement in P3 latencies was

observed in only 9 clients which indicated a lack of
improvement in the speed of processing information in the
other clients.

However, the amplitude of the P3 waves

increased significantly for the entire group (p < .03).

The

findings indicated a 19% improvement in parietal function,
63% improvement in vertex function, and 160% improvement in
frontal brain area function.
The improvements in cognitive functioning were related
to the corrected anemic state with EPO.

These findings also

suggested that part of the uremic syndrome of ESRD clients
receiving hemodialysis is attributed to the effects of the
anemia on the central nervous system and can be reversed
with correction of the anemia.
Improvement in exercise tolerance has also been
observed.

A Canadian Erythropoietin Study Group (cited in

Nissenson,

1989) conducted a randomized double-blind study

in 118 clients receiving hemodialysis and had hemoglobin
levels below 9 gm/dl, including a placebo group.

Clients

treated with EPO exhibited significant improvements in
physical and fatigue dimensions of the kidney disease
specific questionnaire (p < .002) and in a 6-minute walk
test (p = .002).

Another study cited by Nissenson (1989)

indicated that partial correction of the anemia of ESRD
significantly increased oxygen uptake at the anaerobic
threshold (p < .01) and peak peripheral oxygen uptake

17
(p < .002).

Treatment with EPO revealed an increase in

hemoglobin from 5.9 + 0.61 g/dl to 10.9 + 0.59 g/dl
(p < .001) and improvement of exercise tolerance from
partial correction of the anemia.
The studies cited by Nissenson (1989) indicated a
relationship between exercise tolerance and treatment with
EPO.

However, although there was an increase in exercise

tolerance in clients, the level did not return to normal.
This indicated that retained uremic toxins may play a role,
as well as a lack of conditioning in many ESRD clients.
The current study contrasts to the cited studies in
several major areas.

The cited studies were clinical trials

utilizing controlled experimental populations.

The

researchers administered EPO therapy and evaluated its
effect and efficacy on the anemia associated with ESRD by
monitoring hematologic values, as well as other laboratory
values.

These studies also evaluated cognitive and exercise

tolerance following EPO therapy.

In the current study, the

researcher made no attempt to control the variables.

The

effectiveness of EPO on the anemia associated with ESRD as
indicated by an increased hematocrit and an independence
from blood transfusions was reported from data collected.
Similarities to the researcher's study included the use
of hemodialysis and CAPD clients as sample populations,
including clients receiving intravenous or subcutaneous
administrations of EPO.

The studies were also similar in
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reporting the effect of EPO on hematocrit levels and blood
transfusion requirements.

All the studies were concerned

with the long-term effects of EPO therapy on potential
rehabilitation.
If EPO therapy is initiated early, clients with ESRD
may remain more actively involved in home, community, and
vocational activities for a longer period of time.

All of

the reported improvements in exercise tolerance, sexual
potency, cognitive function, and quality of life should have
a major impact on the general well-being of the clients.
By remaining more actively involved in activities of
daily living, it may be possible that fewer clients would
assume the debilitating passivity of the "sick role."

The

locus of control could be shifted from the individual to
other family members or the community, and there would be
less possibility of the individual experiencing decline in
feelings of self-worth, competency, and autonomy.

Chapter III
The Method
Research Design
A descriptive, retrospective investigation was chosen
for this study in order to describe the characteristics of
the effectiveness of recombinant human erythropoietin
therapy on the anemia associated with ESRD as indicated by
an increased hematocrit and an independence from blood
transfusions except for the replacement of blood loss.

The

descriptive, retrospective study design was applicable to
the current research, because the investigator engaging in a
descriptive, retrospective study makes no attempt to control
the variables, but summarizes the status of phenomena of
interest as they exist, and reports the findings as they
have occurred from some cause in the past (Polit & Hungler,
1991).
Variables
Variables of interest.

Variables of interest in this

study were the changes in hematocrit levels, blood
transfusion requirements, the effect of EPO on the blood
pressure and other laboratory values, side effects from EPO,
other forms of therapy (i.e., iron or androgen),
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factors
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affecting efficacy (e.g., inflammation, aluminum toxicity,
and surgery), and EPO dose.
Setting, Population, and Sample
The setting for this study was an ambulatory dialysis
unit in North Mississippi.
clients.

The unit has a total of 242

Services provided include in-center hemodialysis

and home training for hemodialysis or peritoneal dialysis.
There are 196 in-center hemodialysis clients, 7 home
hemodialysis clients, and 39 clients who receive continuous
ambulatory peritoneal dialysis (CAPD).
population, 204 receive EPO therapy.

From the total

The sample consisted

of the clients who were receiving EPO therapy and consented
to participate in the study (N = 100).
Instrumentation
The instrument for data collection was designed by the
researcher.

The instrument included the following

demographic data:

age, ethnicity, and sex.

Other data

consisted of the underlying renal disease, EPO dose,
laboratory values (ferritin, hematocrit, reticulocyte, and
other values that may have been affected by the EPO
therapy).

The instrument also included side effects and

other forms of therapy.

To protect anonymity and

confidentiality of the client, no names were used on the
instrument (see Appendix A).
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Data Collection Procedure
Following approval of the Committee on Use of Human
Subjects in Experimentation of Mississippi University for
Women (see Appendix B ) , permission to conduct this study was
obtained by written consent from the medical director and
the administrator of the dialysis center (see Appendix C ) .
Client permission for use of medical records was obtained by
written consent.

The consent explained the purpose and

procedure for data collection, as well as the ability of the
client to withdraw from the study at anytime up to data
analysis (see Appendix D ) .
Data Analysis
For the purpose of this study, descriptive statistics
including use of means, frequency, and percentages were
utilized.

A paired t test was utilized to analyze the

statistical significance between the pretherapy and
posttherapy data collected with the alpha level set at the
.05 level of significance.

The paired t test was

appropriate for this study because two measures can be
obtained from the same client to determine the average
difference in values before and after a treatment (Polit &
Hungler,

1991).

Limitations
The following limitations were identified;

22
1.

Collection of data was hindered because laboratory

tests identified to determine efficacy of EPO were not
performed as part of the clinical protocol.
2.

Laboratory tests were not performed at consistent

intervals identified by the researcher.
3.

Collection of data was hindered due to inconsistent

record keeping and availability of records within the
clinical setting.
4.

Sample size and data collection were affected

because of the practice of withholding EPO dosage once the
hematocrit reached therapeutic range.

Chapter IV
The Findings
The purpose of this descriptive, retrospective study
was to describe the characteristics of the effectiveness of
EPO therapy on the anemia associated with ESRD.

Increased

posttherapy hematocrit levels and an independence from blood
transfusions, except for the purpose of blood replacement,
were the criteria selected to indicate effectiveness.

A

paired t test was utilized to analyze the statistical
significance between the pretherapy and posttherapy
hematocrit data.

Demographic findings, blood pressures, and

blood transfusions were analyzed using descriptive
statistics,

including means, percentages, and frequencies.

The data collected and analyzed for this study are
presented in this chapter.

Characteristics of the clients

are described first, followed by a description of the
statistical analysis related to pretherapy and posttherapy
data.

Some data were excluded from collection and analysis

due to inconsistencies in monitoring and documentation.
Description of the Sample
The sample (N = 100) consisted of clients from an
ambulatory dialysis unit in North Mississippi.

All clients

were receiving EPO therapy and some form of dialysis.
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There
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were 55 male clients (32% white, 23% black) and 45 female
clients (17% white, 28% black).

Thirty percent of the

clients were between the ages of 23 and 40 years, 51% were
between the ages of 50 and 60 years, and 19% were between
the ages of 70 and 88 years.
was 53.5 years.

The mean age of the clients

All clients had received EPO therapy which

was administered intravenously and/or subcutaneously.
Dosages ranged from 5,000 units to 27,000 units per week.
Analysis of Data
The research question generated was how effective is
EPO therapy in the treatment of the anemia in clients with
ESRD in Mississippi?

A paired t test was utilized to

compare pretherapy hematocrit levels to posttherapy levels
at 1 month, 3 months, and current intervals.

Also,

1-month

posttherapy hematocrits levels were compared to the 3-month
and current hematocrit levels.
There was a significant increase from hematocrits
1 month after receiving EPO therapy, t = -4.12, p < .05.
Hematocrits after 3 months of EPO therapy also increased,
t = -7.45, p < .05.

Significant increases in current

hematocrit levels were also analyzed, t = -8.58, p < .05.
The mean baseline hematocrit was 24.56, and the mean current
hematocrit level was 29.79.
Table 1.

These data are presented in
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Table 1
Comparison of Hematocrit Levels Using the t Test

N

M

sp

Base

100

24.56

4.49

1 month

100

26.47

4.78

Base

100

24.56

4.45

3 months

100

28.96

4.43

Base

100

24.56

4.45

Current

100

29.79

4.18

t

-4.12*

-7.45*

-8.58*

*£ < .05.
There were also significant increases in 3-month
hematocrits when compared to the 1-month hematocrits,
t = -5.39, p < .05.

Current hematocrits compared to the

1-month hematocrits increased significantly as well,
t = -5.34, p < .05.
There was a total of 59 units of packed red blood cells
(PRBC) transfused prior to receiving EPO therapy.

Four

units were given in preparation for surgery or after
surgery,

10 units for gastrointestinal

(GI) bleeding, and 45

units in relationship to low hematocrit levels or an unknown
cause.

Sixty-three units of PRBCs were transfused

posttherapy.

Twelve units were given in preparation for
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surgery or after surgery,

12 units for GI bleeding, and 39

units because of low hematocrits or an unknown cause.
Eighty-eight percent of the clients did not receive blood
transfusions prior to EPO therapy, and 79% of clients did
not receive transfusions posttherapy.

These data are

presented in Table 2.
Table 2
Distribution of Transfusions Pre-EPO and Post-EPO

Units
transferred
prior to EPO
Total

Units
transferred
after EPO

59

63

4

12

GI bleeding

10

12

Low hematocrits/unknown
cause

45

39

Surgical/postsurgical

Therefore, concluding from the statistical analysis of
data, EPO was related to a significant increase in
posttherapy hematocrit levels.

However, no significant

decrease or independence from blood transfusions occurred
posttherapy.
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Additional Information
There was no significant increase on posttherapy blood
pressures when compared to pretherapy blood pressures.

The

mean pretherapy systolic blood pressure was 169.57, and
the mean posttherapy systolic blood pressure was 153.63,
t = 21.25, p > .05.

The mean diastolic blood pressure

pretherapy was 101.33, and the posttherapy mean diastolic
pressure was 86.86, t = 21.19, p > .05.

Therefore, EPO

therapy did not cause an increase in systolic or diastolic
pressures posttherapy.

Chapter V
The Outcomes
The anemia associated with ESRD has been recognized
since 1836.

The etiology of the anemia has been attributed

to many factors, but only in recent years has its
pathogenesis emerged (Eschbach et al., 1990).

However, the

primary cause is thought to be an endocrine deficiency of
erythropoietin (Duff, 1989).
Despite advances in understanding the anemia associated
with ESRD, naturally occurring erythropoietin cannot be
obtained in sufficient quantities for treatment.

However, a

synthetic clone has been developed through genetic coding
(Duff, 1989).

In 1989 the erythropoietin clone, recombinant

human erythropoietin (r-HuEPO, EPO), was approved for use by
the Food and Drug Administration, and EPO has become a
mainstay of therapy (Rosenberg,

1992).

Clinical trials studying the efficacy of EPO have been
conducted and some are ongoing.

However, the purpose of

this study was to evaluate the effectiveness of EPO therapy
in the treatment of the anemia in clients with ESRD in
Mississippi.

Orem's Self-Care Model was used to guide this

descriptive, retrospective study.
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The conclusions.
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implications, and recommendations which evolved from these
findings are presented.
Summary of Significant Findings
The sample consisted of 100 clients from an ambulatory
dialysis unit in Northeast Mississippi.
the group was 53.5 years.

The mean age for

There were 55 male clients

(32%

white, 23% black) and 45 females (17% white, 28% black).
EPO dosages ranged from 5,000 units to 27,000 units per
week.

Analysis of hematocrits for the group was compared.

There was a significant increase for hematocrits;

1 month

after receiving EPO therapy, t = -4.12, p < .05; 3 months
after EPO, t = -7.45, p < .05; and current, t = -8.58,
p < .05.

Significant increases in hematocrits occurred from

1 month to 3 months after therapy, t = -5.39, p < .05, and
in hematocrits from 1 month to current, t = -5.35, p < .05.
With respect to blood transfusions, there was no
significant decrease in the posttherapy analysis.
Eighty-eight percent of the clients did not receive blood
transfusions prior to EPO, as compared to 79% after EPO.
Blood pressures did not increase posttherapy.

The mean

pretherapy systolic blood pressure was 169.57, and the mean
posttherapy systolic pressure was 153.63, t = 21.25,
p > .05.

The mean diastolic blood pressure pretherapy was

101.33, and the posttherapy mean diastolic pressure was
86.86, t = 21.19, p > .05.
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Discussion of Significant Findings
Statistical significance was shown in hematocrit
increases at intervals of 1 month, 3 months, and current
time.

Systolic and diastolic blood pressures were also

shown to have statistical significance.

These findings were

congruent with the studies by Eschbach et al.
Watson et al.

(1987) and

(1990) which found that therapeutic doses of

EPO have a positive effect on hematocrit levels.
by Watson et al.
pressures.

The study

(1990) also demonstrated stable blood

The researcher postulates that clients receiving

therapeutic doses of EPO will experience an increased level
of well-being, potential for rehabilitation to activities of
daily living, and independence from blood transfusions.

The

study by Nissenson (1989) supports this postulation.
This study did not show a significant decrease in blood
transfusion requirements.

However, the researcher concludes

that intervening variables, such as insufficient
documentation by the dialysis unit relating to the need for
transfusions and by the classification of the transfusions
by the researcher, may have altered the findings.

For

instance, if no documentation was available to support the
proper classification for a blood transfusion, the
transfusion was classified under low hematocrits/unknown
cause.

During the chart review, physician orders for stool

specimens for occult blood were observed.

However, no

documentation for collection nor laboratory results were

31
available.

This data may have also been affected by factors

that may affect erythropoietin effectiveness, such as
inflammation, aluminum toxicity, surgical procedures, and
iron deficiency.

Four clients who received transfusions

posttherapy were receiving Desferal, a chelating agent.
Seventeen of the 21 clients who received blood transfusions
posttherapy were also receiving or had received Dextran or
another brand of intravenous iron replacement therapy.
Another intervening variable affecting a significant
decrease or independence from blood transfusions may be the
practice of withholding EPO therapy once the hematocrit has
reached therapeutic range.

This practice is frequently

performed for reimbursement purposes.
Orem's Self-Care Model provides three related theories
which are applicable to the client with ESRD.

These

theories are the Theory of Self-Care, Theory of Self-Care
Deficit, and the Theory of Nursing Systems.

These theories

contain propositions vital to health promotion, such as
health maintenance, prevention, care, rehabilitation, and
functional living with a disease or disability (Riehl-Sisca,
1989).

By functioning within the framework of this theory,

the care and intervention for the client with ESRD would be
more focused and directed toward an optimal level of
rehabilitation.
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Conclusions
The following conclusions were derived from the findings
of this study.

The sample included both male and female

clients, as well as both black and white races in near equal
proportions.

There were significant increases in the

hematocrits after receiving EPO therapy, and the blood
pressures were not increased.

This conclusion is congruent

with other research findings (Eschbach et al., 1987; Watson
et al.,

1990).

The researcher concluded that Orem's Model of Self-care
is applicable to the client with ESRD.

This model will

assist the health provider by directing focused
rehabilitative care.
Implications
A number of implications for nursing science were
derived from this study.

Implications were suggested for

nursing theory, education, and practice.
Nursing theory is tested through research.

Findings

from previous studies did not use Orem's Self-Care Model.
The results of this study indicate the need for continued
use of Orem's Self-Care Model as a conceptual framework for
assessing the effect of EPO therapy on the anemia associated
with ESRD.

The caregiver should not only provide diligent

assessment and intervention, but also formulate functional
documentation for assessment, intervention, and problems
which is vital for continuity of care.
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As the number of clients with ESRD increases due to
improved medical technology, it is essential that nurse
practitioners employed in all areas of health care be
prepared to respond to the educational needs of the client
with ESRD.

With improved health, these clients will

continue vocational and social interaction longer.

The

results of this research should be communicated to the
client with ESRD as a positive result of therapeutic
intervention.

Also, this research indicates the importance

of documentation, compliance, and organization.
Nurses must acknowledge the importance of education
relating to the effects of illness and disease on the
longevity of the client.
and change occur.

Through knowledge, understanding

With continued, positive education, the

nurse can affect the client's health and rehabilitation.
Recommendations
Based on the findings of this study, recommendations
are as follows;
Research
1.

Conduct a similar study to identify the

effectiveness of EPO on the anemia associated with ESRD.
2.

Conduct a similar study utilizing clients on

dialysis and EPO for the same length of time.
3.

Implement a similar study directed at functional

improvements, such as exercise tolerance, sexual
improvement, and feelings of well-being.
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4.

Conduct a study using Orem's Self-Care Model as a

guide for a proposed intervention for education.
Nursing
1.

Develop educational programs for the clients which

promote understanding of ESRD and the therapeutic
interventions used in management of the disease.
2.

Develop medical records which allow for adequate

documentation of health status, laboratory results, and
treatments.
3.

Utilize Orem's Self-Care Model as the conceptual

framework for assessment, intervention, rehabilitation,
prevention, and health promotion.
4.

Become active in health care reform issues which

affect the clients and nurses as health providers.
The findings of this study contribute to the
existing knowledge related to the efficacy of EPO therapy on
the anemia associated with ESRD.

This study adds new

knowledge relating to the client with ESRD in Mississippi.
This study suggests areas for future research which would
impact client care and health care delivery which could
impact all clinicians.
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Agency Memorandum of Agreement
I am Elizabeth Duncan, a registered nurse and a graduate
student at Mississippi University for Women, Columbus,
Mississippi.
As part of my studies, I am conducting a
descriptive, retrospective study on the effectiveness of EPO
therapy in the treatment of the anemia associated with endstage renal disease.
I will be comparing pretherapy
laboratory values and blood transfusion requirements to
posttherapy laboratory and transfusion requirements.
I am requesting your permission to obtain the laboratory and
demographic data needed for this research from your client's
medical records. A consent form for release of information
will be provided to each client receiving EPO and dialysis
for informed consent.
Confidentiality and anonymity of the
clients will be maintained.
No names or identifying
information will appear on any document or in the study.

I have read the above statement and understand the purpose
of the study.
I hereby give my approval for Elizabeth
Duncan to review patient records to obtain the necessary
data for this study.
Date

Administrator's Signature

Date

Medical Director's
Signature

APPENDIX D
INFORMED SUBJECT CONSENT FORM
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Informed Subject Consent Form
I am Elizabeth Duncan, a registered nurse and a graduate
student at the Mississippi University for Women in Columbus,
Mississippi.
As part of my studies, I am conducting
research on the effectiveness of EPO therapy on the anemia
associated with end-stage renal disease.
For this study, I
will need to obtain the following information from your
medical record:
age, sex, race, laboratory values, EPO
dose, blood transfusion and blood pressure data, other types
of therapy, information pertaining to effectiveness and side
effects, and type of underlying renal disease.
I will be
using this information to compare the pretherapy (EPO) data
to the posttherapy data, which will indicate how effective
EPO has been in the treatment of the anemia associated with
end-stage renal disease (ESRD).
Participation in this study is voluntary.
All information
will be confidential and no names will appear on any form or
in the study.
You may withdraw from the study at anytime up
to data analysis.
This study will provide current research information to the
nurses caring for patients with ESRD.
This information will
benefit the patients through teaching by the nurses.

I understand the information given to me.
I understand that
I have the right to withdraw from this study up to data
analysis and my name will not be used.

Date

Client's Signature

